Pharmacological similarities and differences between beta2-agonists.
about
Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease.Role of arformoterol in the management of COPDLong-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safetyDifferences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitization in airway smooth muscle.Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma.Budesonide/formoterol combination in COPD: a US perspective.The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.The preclinical toxicology of salmeterol hydroxynaphthoate.Which of three structures is AZD-3199? WO-2008104790, WO-2008096112 and WO-2008096119.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.Budesonide/salmeterol in fixed-dose combination for the treatment of asthma.
P2860
Q35046032-B9383474-A473-4B6A-B9E0-93FC68961D11Q36443665-B586E266-A516-4576-AE41-9DCBEB00B0DFQ37000770-34040A41-BBA5-4A9F-A00B-17A60141F544Q37070335-6E0C703D-0478-4893-8264-FA305F400B2DQ37115933-E8830E40-5C57-4AC3-BE7E-1A01D38B0341Q37362634-AD821457-F40E-4744-BA32-45D0F69E000BQ37406409-3B492726-11B3-462A-8903-1968AD78A2B5Q37556546-622489DD-7E64-41D3-831F-9A79016C7638Q37805343-3A6E4F7E-B70E-44EB-A632-4C0130E09F55Q42429572-7DA9CDB5-8885-4072-AF68-5ABE2834A21BQ43134820-72F547F6-A74E-4B78-BB8E-5AC3C778EF82Q45948093-BF2C2B12-F387-4875-8ACF-0C996E6B9E81Q47966525-57272202-58E8-4230-9FED-C906AB059D1FQ51602950-95F1C741-9075-47FE-B876-920558C59A9F
P2860
Pharmacological similarities and differences between beta2-agonists.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacological similarities and differences between beta2-agonists.
@ast
Pharmacological similarities and differences between beta2-agonists.
@en
Pharmacological similarities and differences between beta2-agonists.
@nl
type
label
Pharmacological similarities and differences between beta2-agonists.
@ast
Pharmacological similarities and differences between beta2-agonists.
@en
Pharmacological similarities and differences between beta2-agonists.
@nl
prefLabel
Pharmacological similarities and differences between beta2-agonists.
@ast
Pharmacological similarities and differences between beta2-agonists.
@en
Pharmacological similarities and differences between beta2-agonists.
@nl
P356
P1433
P1476
Pharmacological similarities and differences between beta2-agonists.
@en
P356
10.1053/RMED.2001.1139
P478
95 Suppl B
P50
P577
2001-08-01T00:00:00Z